rzeraat commited on
Commit
967510f
·
verified ·
1 Parent(s): d879426

Create train_v8.jsonl

Browse files
Files changed (1) hide show
  1. train_v8.jsonl +21 -0
train_v8.jsonl ADDED
@@ -0,0 +1,21 @@
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
+ {"question": "A patient presents with sudden onset chest pain radiating to the left arm, shortness of breath, diaphoresis, and nausea. ECG shows ST-segment elevation in leads II, III, and aVF. What is the most likely diagnosis and immediate treatment?", "thought": "The clinical presentation is classic for acute myocardial infarction (heart attack). The key symptoms are chest pain, radiation to left arm, dyspnea, diaphoresis, and nausea. The ECG findings of ST-elevation in leads II, III, and aVF specifically indicate an inferior wall MI, which involves the right coronary artery (RCA) in 80-90% of cases. Immediate treatment follows MONA protocol (Morphine, Oxygen if needed, Nitroglycerin if no contraindications, Aspirin) but most importantly, time-sensitive reperfusion therapy. The goal is door-to-balloon within 90 minutes for PCI (percutaneous coronary intervention) or thrombolytics within 30 minutes if PCI not available. Contraindications to nitroglycerin in inferior MI include right ventricular involvement (check right-sided leads for RV4 ST-elevation), which would make the patient preload-dependent.", "answer": "Acute inferior wall ST-elevation myocardial infarction (STEMI), likely RCA occlusion. Immediate treatment: chewable aspirin 325mg, consider nitroglycerin (unless RV involvement), and urgent reperfusion therapy (PCI within 90 minutes or thrombolytics)."}
2
+ {"question": "A pharmaceutical company is considering developing a new drug. The R&D costs are $500 million upfront, with a 20% chance of FDA approval. If approved, expected annual cash flows are $200 million for 10 years. The company's cost of capital is 12%. Calculate the expected NPV and advise on the project.", "thought": "This is a real options/problem with uncertainty problem. Calculate expected PV of cash flows conditional on approval, then multiply by approval probability, subtract initial investment. First, PV of annuity: N=10, I/Y=12%, PMT=200M. PV = 200M × [1 - (1.12)^-10]/0.12 = 200M × 5.6502 = $1,130.04M. Expected PV = 0.20 × 1,130.04M = $226.01M. Expected NPV = 226.01M - 500M = -$273.99M. Negative expected NPV suggests rejecting. But we could also consider option value: the abandonment option after phase trials might reduce downside. However, on pure expected value, it's negative. Risk-adjusted NPV (rNPV) methodology would apply discount rate to each phase probability-weighted cash flow stream.", "answer": "Expected NPV is approximately -$274 million, suggesting rejection. The high upfront cost and low success probability make it unattractive at 12% discount rate, though real options value and staged investment could alter this conclusion."}
3
+ {"question": "In a contract dispute, Party A argues that a force majeure clause excuses performance due to 'unforeseen circumstances.' Party B claims the clause is too vague and unenforceable. The clause states: 'Neither party shall be liable for delays due to unforeseen circumstances beyond their control.' How should a court interpret this under contract law principles?", "thought": "This involves contract interpretation, specifically the enforceability of force majeure clauses. Under common law, force majeure clauses are narrowly construed. The key issues: 1) Is the clause sufficiently definite? The term 'unforeseen circumstances' is ambiguous. Under the vagueness doctrine, courts may find a clause unenforceable if it's too indefinite to provide clear guidance. 2) However, courts often use the doctrine of reasonable construction, interpreting ambiguous terms by looking at industry custom, course of dealing, and commercial reasonableness. 3) The UCC § 2-615 (impracticability) might apply if it's a sale of goods contract. 4) The court would likely require the party invoking the clause to prove the event was truly unforeseeable and beyond control. The clause's vagueness is problematic but may not be fatal if context provides meaning. Better practice is to list specific events (pandemic, war, natural disasters). The court might partially enforce it but require specific proof.", "answer": "Courts would likely enforce the clause but narrowly interpret 'unforeseen circumstances,' requiring Party A to prove the event was truly unforeseeable and beyond reasonable control. The vagueness risks limited enforceability, and courts may imply reasonableness standards from UCC 2-615 or common law impracticability doctrine."}
4
+ {"question": "A 55-year-old male with Type 2 diabetes, hypertension, and hyperlipidemia presents with new-onset microalbuminuria (AER 85 mg/day) and eGFR 68 mL/min. Current meds: metformin 1000mg BID, lisinopril 10mg daily, atorvastatin 20mg daily. Blood pressure is 138/86 mmHg, HbA1c 7.8%. What is the optimal management adjustment?", "thought": "This demonstrates progression of diabetic kidney disease (DKD). Microalbuminuria (30-300 mg/day) with eGFR decline indicates need for intensified therapy. Key interventions: 1) ACE inhibitor (lisinopril) dose should be titrated up to maximum tolerated dose for renal protection and BP control, targeting <130/80 mmHg. 2) Add SGLT2 inhibitor (empagliflozin or dapagliflozin) - shown to reduce albuminuria progression and CV events in DKD, even without severe hyperglycemia. 3) Consider GLP-1 agonist for additional glycemic and renal benefits. 4) Tighten BP control: add thiazide or dihydropyridine CCB if needed. 5) Optimize glycemic control: HbA1c target <7% in CKD, but avoid hypoglycemia. Consider reducing metformin if eGFR drops below 60 (current eGFR 68 is borderline, max dose 2000mg is okay). 6) Check potassium when titrating ACEi. The evidence from EMPA-REG OUTCOME and DECLARE-TIMI 58 shows SGLT2i reduces CKD progression.", "answer": "Up-titrate lisinopril to 20-40mg daily, add SGLT2 inhibitor (dapagliflozin 10mg or empagliflozin 10mg daily), consider intensifying glucose control with GLP-1 RA if needed, and maintain statin therapy. Target BP <130/80 mmHg."}
5
+ {"question": "A company has EBIT of $5 million, interest expense of $1 million, depreciation of $500,000, and tax rate of 25%. Calculate its interest coverage ratio and times interest earned ratio. Is the company at risk of financial distress?", "thought": "Interest coverage ratio = EBIT / Interest Expense = $5M / $1M = 5x. Times Interest Earned (TIE) is the same ratio. Traditional benchmarks: TIE > 3x is generally safe, < 2.5x is risky. At 5x, this appears healthy. However, we should also consider EBITDA coverage: (EBIT + Depreciation) / Interest = ($5M + $0.5M) / $1M = 5.5x. The company has adequate coverage. But risk assessment also requires looking at industry norms, debt maturity schedule, and cash flow volatility. For a stable industry, 5x is comfortable. For cyclical industries, higher coverage may be needed.", "answer": "Interest coverage ratio = 5.0x, EBITDA coverage = 5.5x. Both indicate low risk of financial distress, well above the 3.0x typical safety threshold, assuming stable operations."}
6
+ {"question": "A police officer conducts a warrantless search of a vehicle incident to arrest. The arrest was for driving with a suspended license. The search revealed drugs in the trunk. Under the Fourth Amendment and Arizona v. Gant (2009), is the evidence admissible?", "thought": "This involves the automobile exception and search incident to arrest post-Arizona v. Gant. Key holding in Gant: Police may search a vehicle incident to arrest only if: (1) the arrestee is within reaching distance of the vehicle at the time of the search, OR (2) it's reasonable to believe evidence relevant to the crime of arrest might be found in the vehicle. Here, the arrest was for driving with suspended license - a status offense with no evidence to be found. The officer cannot justify the search under Gant's second prong. The first prong likely fails too if the suspect was secured away from the vehicle. The search would be unconstitutional. Under the exclusionary rule (Mapp v. Ohio), the drug evidence would be suppressed as fruit of the poisonous tree. However, if the officer could have discovered it through inventory search or other independent justification, it might be saved by inevitable discovery doctrine.", "answer": "The evidence is likely inadmissible. Under Arizona v. Gant, a search incident to arrest for driving with a suspended license is unconstitutional unless the arrestee could access the vehicle or evidence of that crime might be found, neither of which applies. The drugs would be suppressed under the exclusionary rule."}
7
+ {"question": "A patient with schizophrenia on clozapine develops a fever of 38.5°C, sore throat, and absolute neutrophil count (ANC) of 800/mm³. What is the diagnosis and immediate action?", "thought": "This is agranulocytosis, a serious adverse effect of clozapine occurring in ~1% of patients, typically within first 6 months. The triad of fever, sore throat, and low ANC (<1000/mm³) is classic. Clozapine requires mandatory ANC monitoring via the REMS program. ANC 800/mm³ falls in the moderate range (500-1000). Immediate actions: 1) Discontinue clozapine immediately - do not wait for confirmation. 2) Hospitalize patient for monitoring and infection workup. 3) Start broad-spectrum antibiotics empirically given infection risk. 4) Consider G-CSF (granulocyte colony-stimulating factor) to accelerate recovery. 5) Do not rechallenge with clozapine. Alternative antipsychotics must be considered. The differential includes benign ethnic neutropenia (BEN), but fever/sore throat suggests true agranulocytosis.", "answer": "Clozapine-induced agranulocytosis. Immediate action: discontinue clozapine, hospitalize, start broad-spectrum antibiotics, monitor ANC closely, consider G-CSF, and do not rechallenge with clozapine."}
8
+ {"question": "A project requires initial investment of $10 million with cash flows: Year 1: $2M, Year 2: $3M, Year 3: $4M, Year 4: $5M. At 10% discount rate, calculate discounted payback period and advise if required payback is 3 years.", "thought": "Calculate discounted cash flows: Year 1: 2/1.10 = 1.818M (cumulative: 1.818M). Year 2: 3/1.10² = 3/1.21 = 2.479M (cumulative: 4.297M). Year 3: 4/1.10³ = 4/1.331 = 3.005M (cumulative: 7.302M). Year 4: 5/1.10⁴ = 5/1.464 = 3.415M (cumulative: 10.717M). The initial investment of 10M is recovered between years 3 and 4. At end of year 3, shortfall = 10 - 7.302 = 2.698M. Fraction of year 4 needed = 2.698/3.415 = 0.79 years. So discounted payback = 3.79 years. Since required payback is 3 years, this project fails the criterion. However, NPV should also be considered: NPV = -10 + 1.818 + 2.479 + 3.005 + 3.415 = 0.717M (positive), so it might be acceptable despite longer payback.", "answer": "Discounted payback period is approximately 3.79 years, exceeding the 3-year requirement. However, NPV is positive ($717K), suggesting the project creates value despite longer payback."}
9
+ {"question": "In a product liability case, a manufacturer argues that the plaintiff modified the product after purchase, which caused the injury. Under the 'substantial change' defense and Restatement (Third) of Torts, what must the manufacturer prove to avoid liability?", "thought": "This involves the comparative fault and product modification defenses. Under Restatement (Third) of Torts: Products Liability § 16, a seller is not liable if the plaintiff's modification was 'substantial' and the modification was the proximate cause of harm. The manufacturer must prove: 1) The plaintiff made a substantial change to the product's design or warnings after it left the seller's control. 2) This modification was not reasonably foreseeable by the manufacturer. 3) The modification was the actual and proximate cause of the injury. 4) The product was safe when it left the manufacturer. However, if the modification was foreseeable (common user alterations), the manufacturer may still be liable for failure to warn or design defect. The case will also examine comparative fault under state law, which may apportion damages rather than completely bar recovery.", "answer": "The manufacturer must prove the plaintiff made a substantial, unforeseeable modification that was the proximate cause of injury. If modification was foreseeable, liability may still attach, though damages might be reduced under comparative fault principles."}
10
+ {"question": "A 32-year-old female presents with 3 days of dysuria, frequency, and suprapubic pain. Urinalysis shows pyuria and positive nitrites. She is 8 weeks pregnant. What is the optimal antibiotic choice and duration?", "thought": "This is acute cystitis in pregnancy, requiring treatment to prevent progression to pyelonephritis, which increases risk of preterm labor. Key considerations: 1) Safety profile for fetus (first trimester organogenesis). 2) Avoid contraindicated antibiotics: Nitrofurantoin is generally safe but avoid near term (not relevant here). Trimethoprim is contraindicated in first trimester due to folate antagonism and risk of neural tube defects. Fluoroquinolones avoided due to cartilage toxicity potential. Doxycycline is contraindicated. Preferred agents: Amoxicillin-clavulanate 500/125mg TID for 3-7 days, or cephalexin 500mg QID for 3-7 days, or fosfomycin 3g single dose (if available). Check local resistance patterns. E. coli resistance to amoxicillin is high, so amoxicillin-clavulanate is better. Follow-up culture recommended in pregnancy to ensure clearance.", "answer": "Amoxicillin-clavulanate 875/125mg BID for 5-7 days, or cephalexin 500mg QID for 5-7 days. Nitrofurantoin 100mg BID for 5 days is alternative if G6PD normal. Avoid TMP-SMX in first trimester. Obtain urine culture."}
11
+ {"question": "A company has a debt-to-equity ratio of 2.0, total assets of $15 million, and a net profit margin of 8% on sales of $10 million. Calculate ROE using DuPont analysis and identify the driving factor.", "thought": "Total assets = $15M. Debt-to-equity = 2.0 → D/E = 2 → D/(D+E) = 2/3, E/(D+E) = 1/3. Since total assets = D + E = $15M, Equity = $15M × 1/3 = $5M, Debt = $10M. Net income = 8% × $10M = $800K. ROE = NI/Equity = 800K/5M = 0.16 = 16%. DuPont breakdown: ROE = Net profit margin × Asset turnover × Equity multiplier. Asset turnover = Sales/Assets = 10M/15M = 0.667. Equity multiplier = Assets/Equity = 15M/5M = 3. So ROE = 0.08 × 0.667 × 3 = 0.16. The high ROE is primarily driven by financial leverage (equity multiplier of 3.0), not operational efficiency (low asset turnover of 0.667).", "answer": "ROE is 16%. DuPont analysis shows it's driven primarily by high financial leverage (equity multiplier of 3.0) rather than operational efficiency, indicating significant debt risk."}
12
+ {"question": "A defendant is convicted of burglary based solely on eyewitness testimony. The defense moves for acquittal under Jackson v. Virginia, arguing insufficient evidence. What standard must the prosecution meet and how will the court likely rule?", "thought": "Under Jackson v. Virginia (1979), the standard is whether, viewing the evidence in the light most favorable to the prosecution, any rational trier of fact could have found the essential elements of the crime beyond a reasonable doubt. This is a very deferential standard. The court will not weigh credibility or second-guess the jury. Eyewitness testimony alone can be sufficient if the witness was credible, had opportunity to observe, and identification was reliable. The court will consider: 1) Whether the testimony, if believed, establishes each element; 2) The jury's role is to assess credibility. Under Jackson, the conviction will stand unless no rational jury could credit the testimony. Only if the ID is so unreliable (e.g., fleeting glimpse, cross-racial, no prior familiarity) might the court grant acquittal. Post-conviction relief also faces AEDPA deference under 28 U.S.C. § 2254.", "answer": "The prosecution must show that viewing evidence favorably to them, a rational jury could find guilt beyond reasonable doubt. The conviction will likely stand unless the eyewitness testimony is so inherently incredible that no rational jury could rely on it given the viewing conditions."}
13
+ {"question": "A 68-year-old male with COPD (FEV1 45% predicted) and acute exacerbation requires oxygen therapy. His SpO2 is 82% on room air. What is the target oxygen saturation and why is over-oxygenation dangerous?", "thought": "In COPD exacerbations, target SpO2 is 88-92%, not 94-98% as in other conditions. Rationale: Chronic CO2 retainers develop respiratory drive dependence on hypoxic drive (peripheral chemoreceptors) rather than central CO2 drive due to chronic elevation. Over-oxygenation (SpO2 > 92%) can: 1) Suppress hypoxic drive, causing hypoventilation and CO2 narcosis. 2) Reverse hypoxic pulmonary vasoconstriction, increasing V/Q mismatch and raising CO2. 3) Haldane effect: oxygenated blood carries less CO2 as carbamino compound, raising PaCO2. Aim for 88-92% using controlled oxygen delivery (Venturi mask) and monitor ABGs. If CO2 rises despite controlled O2, consider NIPPV or intubation.", "answer": "Target SpO2 is 88-92%. Over-oxygenation suppresses hypoxic respiratory drive, worsens V/Q mismatch, and causes hypercapnia via Haldane effect, potentially leading to respiratory failure."}
14
+ {"question": "A bond with face value $1000, 8% coupon rate (semiannual payments), matures in 5 years. Current YTM is 10%. Calculate its current price and duration. If rates rise by 1%, estimate the price change using duration.", "thought": "Coupon payment = 8% × 1000 / 2 = $40 semiannual. YTM per period = 10%/2 = 5%. Periods = 5×2 = 10. Price = Σ(40/(1.05)^t) + 1000/(1.05)^10 for t=1 to 10. PV of coupons: 40 × [1 - (1.05)^-10]/0.05 = 40 × 7.7217 = $308.87. PV of face value: 1000/(1.05)^10 = 1000/1.6289 = $613.91. Total price = $922.78. Duration calculation: Weighted average time. Macaulay duration = [Σ(t × CFt/(1+y)^t)]/Price. Calculate each period's present value weight: t=1: 40/1.05 = 38.10; t=2: 40/1.1025 = 36.28; etc. Sum of t×PV = approx 7411. Duration = 7411/922.78 = 8.03 periods = 4.015 years. Modified duration = Macaulay/(1+y) = 4.015/1.05 = 3.824 years. Price change estimate: ΔP/P ≈ -D_mod × Δy = -3.824 × 0.01 = -3.82%. New price ≈ $922.78 × (1 - 0.0382) = $887.50.", "answer": "Current price ≈ $922.78. Modified duration ≈ 3.82 years. Estimated price decline ≈ 3.8% to $887.50 if rates rise 1%."}
15
+ {"question": "A state law requires voters to show government-issued photo ID. Plaintiffs sue, alleging it violates the Equal Protection Clause by burdening minorities who lack ID. What level of scrutiny applies and what must the state prove?", "thought": "This involves voting rights and equal protection. Under Burdick v. Takushi (1992), voting restrictions are analyzed under Anderson-Burdick balancing test: weight of burden on voters vs. state's interests. This is not strict scrutiny (which applies to severe burdens on fundamental right) but heightened scrutiny for moderate burdens. Under Crawford v. Marion County (2008), voter ID laws are generally permissible if they serve important regulatory interests (preventing fraud, ensuring confidence) and don't impose severe burdens. The state must show: 1) Important state interest in election integrity. 2) The law is narrowly tailored (doesn't burden more than necessary). 3) Any burden is offset by availability of free IDs and accessibility. Plaintiffs must show actual, not speculative, burden on a particular group. The state's interest in preventing fraud is compelling, but the law must not be a poll tax or discriminatory in effect.", "answer": "Anderson-Burdock balancing test applies. The state must show an important interest in election integrity and that the law doesn't impose severe burdens. Voter ID laws are generally upheld if free IDs are available and the burden on voters is minimal, though discriminatory effect could trigger stricter scrutiny under the Voting Rights Act."}
16
+ {"question": "A 45-year-old female with rheumatoid arthritis on methotrexate 15mg weekly presents with fever, cough, and bilateral infiltrates. Chest CT shows ground-glass opacities. She was recently started on infliximab. What is the most likely diagnosis and workup?", "thought": "This is an immunosuppressed patient with TNF-α inhibitor (infliximab) plus methotrexate, putting her at high risk for opportunistic infections. The presentation suggests Pneumocystis jirovecii pneumonia (PJP). Key clues: immunosuppression, subacute onset, diffuse ground-glass opacities, hypoxemia. However, differential includes: bacterial pneumonia, TB reactivation (increased risk with TNF inhibitors), fungal infection (aspergillus, histoplasma), viral (CMV). Workup: 1) Induced sputum or bronchoscopy with BAL for PJP DFA or PCR. 2) Serum β-D-glucan (sensitive for PJP). 3) Respiratory viral panel. 4) Sputum cultures and AFB smear/culture for TB. 5) Check her vaccination status - was she screened for latent TB before starting infliximab? If PJP suspected, start empiric high-dose TMP-SMX (15-20 mg/kg/day TMP) and steroids if severe hypoxemia. Prophylaxis should have been considered before starting biologic therapy if she had risk factors.", "answer": "Most likely Pneumocystis jirovecii pneumonia. Workup: induced sputum/BAL for PJP PCR, serum β-D-glucan, respiratory viral panel, TB testing, sputum cultures. Start empiric TMP-SMX immediately if suspicion is high."}
17
+ {"question": "A company is evaluating a merger where the target has $50M debt at 8% and equity valued at $75M. The acquirer can refinance debt at 6% post-merger. Tax rate is 30%. Calculate the present value of interest tax shields assuming debt is permanent.", "thought": "Current debt = $50M. Current interest = 8% × 50M = $4M. New interest = 6% × 50M = $3M. The merger benefit is interest savings of $1M annually, not the full interest tax shield. Tax shield = Interest × Tax rate. Old tax shield = $4M × 30% = $1.2M. New tax shield = $3M × 30% = $0.9M. However, the refinancing benefit is the $1M interest savings, which is after-tax: $1M × (1-0.30) = $700K. If debt is permanent, PV of perpetual tax shield at new rate: $0.9M / 0.06 = $15M. PV of old tax shield: $1.2M / 0.08 = $15M. The PV doesn't change because tax shield value is independent of interest rate when debt level is constant. But the refinancing creates value through lower interest expense: PV of savings = $700K / 0.06 = $11.67M.", "answer": "PV of new tax shield = $0.9M / 6% = $15 million. PV of after-tax interest savings from refinancing = $700,000 / 6% = $11.67 million. Total value created = $11.67 million."}
18
+ {"question": "A public university denies a student group funding because its mission is 'primarily religious.' The group sues under First Amendment. How should the court rule under Rosenberger v. Rector (1995)?", "thought": "This involves the Establishment Clause and Free Speech Clause in public university funding. Under Rosenberger v. University of Virginia (1995): 1) University funding of student groups is a limited public forum. 2) Viewpoint discrimination is prohibited - denying funds because speech is religious is unconstitutional. 3) The Establishment Clause does not justify viewpoint discrimination against religious speech if funding is available to secular groups. The Supreme Court held that neutral funding criteria that fund secular and religious groups equally does not violate Establishment Clause. The university must show it's using neutral, objective criteria. If other mission-based groups receive funding, denying religious group is unconstitutional viewpoint discrimination. However, this only applies if the funding comes from mandatory student fees, not direct government appropriation. The court should rule for the student group, ordering equal access to funding.", "answer": "The university violated the First Amendment by engaging in viewpoint discrimination. Under Rosenberger, religious student groups cannot be denied equal access to generally available funding based on their religious viewpoint, as the Establishment Clause does not require exclusion from neutral funding programs."}
19
+ {"question": "A 28-year-old male with HIV (CD4 120, not on ART) presents with severe headache, confusion, and fever. LP shows opening pressure 35 cm H2O, WBC 45 (lymphocytic), protein 85 mg/dL, glucose 35 mg/dL (serum glucose 90). India ink stain is positive. What is the diagnosis and treatment?", "thought": "This is cryptococcal meningitis, an AIDS-defining opportunistic infection occurring when CD4 < 100. Key features: subacute meningitis symptoms, high opening pressure, lymphocytic pleocytosis, low glucose, high protein, positive India ink (though sensitivity only ~50%). The high opening pressure is crucial - requires therapeutic lumbar puncture to drain CSF to <20 cm H2O. Treatment: Induction with amphotericin B deoxycholate (0.7 mg/kg/day) + flucytosine (100 mg/kg/day) for 2 weeks, then consolidation with fluconazole 400mg daily for 8 weeks, then maintenance fluconazole 200mg daily until CD4 > 100 for 6+ months on ART. Must also start ART within 4-6 weeks (not immediately, to avoid IRIS). Monitor LFTs with azoles. Check for ICP elevation daily and repeat LPs as needed.", "answer": "Cryptococcal meningitis. Treatment: Amphotericin B + flucytosine induction for 2 weeks, then fluconazole consolidation for 8 weeks, followed by maintenance therapy. Daily therapeutic lumbar punctures to reduce opening pressure to <20 cm H2O, and start ART at 4-6 weeks."}
20
+ {"question": "A pension fund must pay $10M in 10 years. It can invest in 5-year zero-coupon bonds yielding 6% and 20-year zeros yielding 7%. How much should it invest in each to immunize against interest rate risk (duration matching)?", "thought": "Immunization requires asset duration = liability duration. Liability is a single payment in 10 years, so its duration = 10 years. Let x = proportion in 5-year bonds (duration = 5), 1-x = proportion in 20-year bonds (duration = 20). We need: 5x + 20(1-x) = 10 → 5x + 20 - 20x = 10 → -15x = -10 → x = 2/3. So invest 66.7% in 5-year zeros and 33.3% in 20-year zeros. Present value of liability = 10M / (1+r)^10. Need to select r - use yield curve? For simplicity, use average yield. But immunization also requires PV(assets) = PV(liability). Let y = yield for each bond category. 5-year bond price = 1000/(1.06)^5 = $747.26 per $1000 face. 20-year bond price = 1000/(1.07)^20 = $258.42. Solve for amounts.", "answer": "Invest 66.7% of assets in 5-year zeros and 33.3% in 20-year zeros to achieve average duration of 10 years. This matches liability duration and immunizes against small interest rate changes."}
21
+ {"question": "A defendant is charged with murder but found incompetent to stand trial. After 6 months of treatment, he's restored to competency. Can he be tried if the treatment involved involuntary medication that altered his memories of the crime? Riggins v. Nevada analysis.", "thought": "This implicates due process and right to fair trial under Riggins v. Nevada (1992) andSell v. United States (2003). Key issues: 1) Forcible medication must be medically appropriate, substantially unlikely to cause side effects that undermine trial fairness, and necessary for safety or adjudication. 2) Riggins held that involuntary medication can violate due process if it prevents defendant from assisting counsel or alters demeanor dramatically. 3) If medication impairs memory of the crime, it may prevent defendant from testifying in his own defense or assisting in fact investigation, violating right to effective participation. However, if the medication was necessary to restore sanity/competence and no less intrusive alternative existed, and the side effects don't render trial fundamentally unfair, it may be permissible. The court must conduct a Sell hearing: medication must be (i) medically appropriate, (ii) substantially unlikely to impair defense, (iii) necessary for adjudication. Memory impairment likely fails prong (ii). Defense could move to suppress defendant's statements made while medicated.", "answer": "Trial may be unconstitutional if involuntary medication substantially impaired memory, preventing effective defense participation. Under Riggins/Sell, the court must find medication was medically necessary, side effects minimal, and no less intrusive alternatives existed. Memory impairment likely violates due process."}